Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $239.71M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 0.82M
Average 1.12M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +175.9% | -17.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +175.9% over three years. Forward estimates point to Revenue at -17.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Cue Biopharma, Inc. NASDAQ:CUE | $117.10M | $16.12 | Not rated | -6.7 | -13.07% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -78.67% |
Equillium, Inc. NASDAQ:EQ | $81.80M | $1.29 | Not rated | -15.3 | +10.89% |
Coeptis Therapeutics, Inc. NASDAQ:COEP | $38.62M | $10.99 | Not rated | -8.3 | -10.24% |
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | $36.15M | $0.49 | Not rated | -3.8 | -50.36% |
OS Therapies Incorporated AMEX:OSTX | $34.87M | $0.75 | Not rated | -2.0 | -29.01% |
Karyopharm Therapeutics Inc. NASDAQ:KPTI | $408,266.00 | $0.02 | Not rated | -1.0 | +21.70% |
Continue the stock analysis
Jump to another research area for this company.